RESPONSE OUTCOMES OF CONCURRENT CHEMORADIOTHERAPY (CCRT) FOR STAGE III NASOPHARYNGEAL CARCINOMA

Authors

  • Feri Danil Otorhinolaryngology Department, Gatot Soebroto Central Army Hospital, Jakarta, Indonesia

DOI:

https://doi.org/10.32734/ijnpc.v2i01.3596

Keywords:

nasopharyngeal carcinoma, stage III, concurrent, chemo radiotherapy

Abstract

Introduction:

Nasopharyngeal carcinoma (NPC) is a rare malignancy with an incidence of 0.5-2 per 100,000 in Europe and the United States [1]. NPC has high prevalence in certain regions of the world, especially in Southeast Asia with a poor prognosis. In Indonesia, the prevalence  of NPC is 6.2/100 000, with 13 000 yearly new cases, [2]. NPC is the forth most cancer found in Indonesia.

Case Report:

This paper reported a case of 39 years old man with nasopharyngeal carcinoma and subsequently underwent concurrent chemoradiotherapy (CCRT).

Conclusion:

The purpose of this paper is to explain experience at one of the largest single-centre of weekly cisplatin concurrently with radiotherapy with potential to be an optimal therapeutic regiment in the nonsurgical management of squamous cell carcinoma of head and neck (SCCHN) clinical stage III.

References

[1] Ferlay J. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancerbase. 2001.
[2] Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chinese journal of cancer. 2012;31(4):185.
[3] Chan A, Grégoire V, Lefebvre J-L, Licitra L, Hui EP, Leung S, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment andfollow-up. Annals of oncology. 2012;23:vii83-vii5.
[4] Network NCC. NCCN clinical practice guidelines in oncology (NCCN guidelines®) head and neck cancers version 2.2017. 2017.
[5] Chen Q-Y, Wen Y-F, Guo L, Liu H, Huang P-Y, Mo H-Y, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. Journal of the National Cancer Institute. 2011;103(23):1761-70.
[6] Cheng SH, Tsai SY, Yen KL, Jian JJ-M, Chu N-M, Chan K-Y, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. Journal of Clinical Oncology. 2000;18(10):2040-5.
[7] Xu T, Hu C, Wang X, Shen C. Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma. Oral oncology. 2011;47(5):408-13.
[8] Ferlay J. Cancer incidence, mortality and prevalence worldwide. GLOBOCAN. 2004.
[9] Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. New England Journal of Medicine. 2001;345(26):1890-900.
[10] Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert review of anticancer therapy. 2006;6(7):1111-8.
[11] Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer. 1995;75(6):1343-53.
[12] Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. International Journal of Radiation Oncology* Biology* Physics. 1989;17(3):467-76.
[13] Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S, Endo K. Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx. 2012;39(2):137-44.
[14] Lo SS, Lu JJ. Natural history, presenting symptoms, and diagnosis of nasopharyngeal carcinoma. Nasopharyngeal Cancer: Springer; 2010. p. 41-51.
[15] Bailey BJ, Johnson JT, Newlands SD. Head & neck surgery--otolaryngology: Lippincott Williams & Wilkins; 2006.

Published

2020-03-18

How to Cite

1.
Danil F. RESPONSE OUTCOMES OF CONCURRENT CHEMORADIOTHERAPY (CCRT) FOR STAGE III NASOPHARYNGEAL CARCINOMA. IJNPC [Internet]. 2020Mar.18 [cited 2020May27];2(01):28-30. Available from: https://talenta.usu.ac.id/IJNPC/article/view/3596